SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Turbo Energy SA provides energy solutions. It engages in the developing, manufacturing and distributing of photovoltaic products. The company was founded on September 18, 2013 and is headquartered in Valencia, Spain.

Turbo Energy S.A. - ADR

TURB is trending due to a recent $53 million contract, leading to a significant surge in price and high trading volume as the community discusses potential price targets and whether the run is sustainable. Some traders point to a low float and possible short squeeze, while others caution about pump-and-dump schemes. The stock's volatility and potential for further gains are key points of discussion.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending amid retail speculation about potential government contracts, fueled by a recent congressional stock purchase disclosure, with community members drawing comparisons to Palantir ($PLTR). Bullish investors are actively discussing chart patterns and the potential for a short squeeze, emphasizing the company's AI-driven solutions in defense and security. The overall sentiment focuses on potential gains amid growing interest in AI for government applications.

MicroAlgo, Inc. operates as a holding company, which engages in the development and application of bespoke central processing algorithms. Its services include algorithm optimization, accelerating computing power without the need for hardware upgrades, lightweight data processing, and data intelligence. The company was founded May 14, 2018 and is headquartered in New York, NY.

MicroAlgo Inc

MLGO is trending as traders discuss its potential for a short squeeze and a possible pump, reminiscent of past runs. Community members are weighing in on its low float, high short interest, and the company's financials, while acknowledging its history of dilution. Some investors are drawing comparisons to other AI and crypto-related stocks, hoping for a similar breakout.

FGI Industries Ltd. engages in the supply of kitchen and bath products. Its products fall under the following categories: Sanitaryware, Bath Furniture, Shower Systems and Other. The Sanitaryware category offers bath products such as toilets, sinks, pedestals and toilet seats. The Bath Furniture category deals with wood and wood-substitute furniture for bathrooms, including vanities, mirrors, laundry and medicine cabinets, and other storage systems. The Shower Systems category includes a range of shower-related products such as shower walls, shower doors and shower basins. The Others category includes shower door and shower systems products, custom kitchen cabinetry, and other accessory items. The company was founded on May 26, 2021 and is headquartered in East Hanover, NJ.

FGI Industries Ltd

FGI is trending due to a potential short squeeze, with community members drawing comparisons to recent runners like $TURB and $QMMM. The stock saw trading halts and significant pre-market gains, leading to discussions about its nano float and possible price targets. Community members highlight insider ownership and fundamentals, suggesting shorts must cover soon.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC Class B Ordinary Shares

BREA is trending due to news regarding its acquisition of a majority stake in Italian Serie B football club Juve Stabia, leading to significant price volatility and trading halts. The community is discussing the stock's potential for further gains, as well as the risk of a pullback after the recent surge. Some investors see BREA as undervalued, citing its unique business model and the involvement of institutional investors.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers is trending due to an FDA warning letter regarding allegedly misleading claims about compounded semaglutide products, sparking debate about the severity of the issue. While some investors see this as a buying opportunity amidst the dip, others express concerns about potential legal issues and weakening financial performance. Community members are actively discussing the impact on the company's growth and valuation, with opinions split between those who see a short-term setback and those who anticipate long-term consequences.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around a recent dip, viewing it as a buying opportunity before the next leg up. Key talking points include upcoming token burns at 2000 watchers, a listing on Bifinance, a live 'Biggest Buy Contest', and staking utility, all contributing to bullish sentiment for this Solana project.

Jumia Technologies AG engages in the provision of logistic services. It operates a pan-African e-commerce platform. It operates through the following geographical segments: West Africa, North Africa, East and South Africa, Europe, United Arab Emirates, and Others. The company was founded by Jeremy Hodara, Sacha Poignonnec, Peter Allerstorfer, Manuel Koser, Tunde Kehinde, and Raphael Afaedor in 2012 and is headquartered in Berlin, Germany.

Jumia Technologies Ag - ADR

Jumia ($JMIA) is trending following an RBC Capital upgrade citing improved supply chains and easing currency pressures. The community is actively discussing the potential for a short squeeze, while also cautioning against the inherent risks of such rapid gains. Some investors point to the company's potential in the growing African e-commerce market.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop ($GME) is trending as traders discuss recent positive price action and the potential for a short squeeze, fueled by upcoming warrant distribution; the community is analyzing technical indicators and speculating on the impact of these warrants on short positions. Some traders are also discussing potential catalysts, including a possible acquisition and the company's inclusion in the S&P 500. A few are pointing to past bagholding from some of the pumpers.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk ($TTD) is trending as the stock experiences volatility following analyst downgrades and news of competition intensifying. Community discussions revolve around whether this dip presents a buying opportunity or signals a longer-term struggle amid concerns about slowing growth. Investors are closely watching support levels and speculating on potential catalysts, including a shareholder meeting and future earnings reports, while also considering the broader ad-tech landscape.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H.C. Wainwright on Monday set a price target of $11 for CervoMed (CRVO) shares while keeping a ‘Neutral’ rating. The target implies a premium of nearly 5% from the stock’s closing price on Friday.The regulatory outlook for Neflamapimod should be clarified in the near term, the analyst told investors in a research note. The firm noted CervoMed is actively preparing for discussions with the U.S. Food and Drug Administration (FDA), which management expects to take place during the fourth quarter.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_12_48_27_PM_png_0e348d0430.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:40 p.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Late in July, Cervomed <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">said</a> that Neflamapimod continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial. Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening at week 32 of treatment, the company said.DLB is a type of dementia characterized by the presence of Lewy bodies, which are protein clumps, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.The company then also confirmed that it is looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.In the second quarter of 2025, CervoMed also enrolled the first patients in a mid-stage trial of Neflamapimod in patients recovering from acute stroke. It also initiated a mid-stage trial of Neflamapimod in patients with the nonfluent/agrammatic variant of primary progressive aphasia (PPA) – a subtype of frontotemporal dementia (FTD).Neflamapimod was granted Orphan Drug designation for the treatment of FTD in November 2024. Frontotemporal dementia (FTD) is a group of brain disorders characterized by the progressive degeneration of the brain's frontal and temporal lobes, leading to changes in personality, behavior, and language.According to data from Koyfin, all six analysts covering CervoMed rate it a ‘Buy’. The stock has an average price target of $21.50.CRVO stock is up 334% this year but down approximately 36% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/stellantis-stock-slips-after-us-regulator-probes-287000-chrysler-minivans/chwhGZoRdrX">Stellantis Stock Slips After US Regulator Probes 287,000 Chrysler Minivans Over Concerns Regarding Electric Power Steer</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.

CervoMed Gets $11 Price Target From HC Wainwright, Analyst Says Regulatory Outlook For Experimental Dementia Drug Should Be Clear Soon 

Equity

H.C. Wainwright’s price target implies a premium of nearly 5% from the stock’s closing price on Friday.


Sangamo Therapeutics (SGMO) Reports Q2 Loss, Lags Revenue Estimates

Sangamo (SGMO) delivered earnings and revenue surprises of -14.29% and -9.38%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Niagen Bioscience (NAGE) Q2 Earnings and Revenues Surpass Estimates

Niagen Bioscience (NAGE) delivered earnings and revenue surprises of +100.00% and +8.99%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of +1,166.67% and +14.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

CervoMed Inc. (CRVO) announced on Monday that its drug continued to slow disease progression in a type of dementia during the extension phase of its mid-stage trial.Dementia with Lewy Bodies (DLB) patients treated with Neflamapimod showed a 54% risk reduction in clinically significant worsening compared to control at week 32 of treatment based on Clinical Dementia Rating Sum of Boxes, a standard measure of clinical progression in dementia trials, the company said. &nbsp;The risk reduction improved to 64% among patients with minimal Alzheimer’s disease co-pathology, it added.DLB is a type of dementia characterized by the presence of Lewy bodies, which are clumps of protein, in the brain. It is the second most common form of neurodegenerative dementia, following Alzheimer's disease.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/CRVO">CervoMed</a> trended in the ‘extremely bullish’ territory, while message volume is at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_12_07_40_PM_png_3051704308.webp" alt="CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits" width="626" height="60"><figcaption>CRVO's Sentiment Meter and Message Volume as of 12:05 p.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user indicated they are awaiting analysts’ takes on the news.<stembedurl>https://stocktwits.com/generaltom/message/622721810</stembedurl>Another user praised the result and highlighted that they have loaded up on the stock.<stembedurl>https://stocktwits.com/roquefort/message/622678785</stembedurl>Lawrence S. Honig, Professor of Neurology at Columbia University Irving Medical Center, stated that this level of effect, if confirmed in a Phase 3 pivotal trial, would be an important advance in the unmet treatment needs of patients with DLB, the second most common dementia.The company is now looking forward to initiating late-stage trials and is preparing to meet with the U.S. Food and Drug Administration in the fourth quarter to align on the trial design.The firm also said that at week 32 of the extension phase, there was a statistically significant reduction from baseline in plasma levels of glial fibrillary acidic protein (GFAP).Plasma levels of glial fibrillary acidic protein (GFAP) are generally low in healthy individuals but can increase with certain neurological conditions.No new safety signals were identified during the extension phase of the trial, it added.CRVO stock is up by over 300% this year but down by 33% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/graphjet-ceo-says-company-expects-to-benefit-from-16.5-billion-tesla-samsung-deal/choes4fR5x3">Graphjet Stock Rockets 36% After CEO Says Company Expects To Benefit From $16.5B Tesla-Samsung Deal: Retail Wants To Buy More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Close up of female hand touching stock market analysis digital display screen TradingView chart, analyzing investment and financial trading data in candlestick chart on a touch screen interface.

CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock

The company is now poised to initiate late-stage trials for Neflamapimod. 

CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?

CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of CervoMed Inc. (<a class="mention" data-mention="$CRVO" data-symbol-id="CRVO" href="https://stocktwits.com/symbol/CRVO" target="_blank">$CRVO</a>) jumped more than 12% in pre-market trading on Wednesday, on course to snap a two-day losing streak, and grabbed retail attention.The company announced that its oral investigational drug, neflamapimod, was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of frontotemporal dementia (FTD).Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB), is showing promise in targeting specific pathogenic mechanisms associated with FTD.&nbsp;The designation recognizes the drug’s potential to address a rare condition affecting approximately 50,000 to 60,000 people in the U.S., with a higher prevalence in Europe and potentially in Asia and Latin America.John Alam, CEO of CervoMed, highlighted the significance of this milestone, noting that the company is actively working with clinical experts to design a proof-of-principle study for FTD while preparing to move neflamapimod into a Phase 3 trial for DLB in mid-2025.&nbsp;The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.Analyst Jason Kolbert from D. Boral Capital maintained a ‘Buy’ rating on the stock, setting a price target of $34, which implies over four times upside from the stock’s previous close.<figure class="image"><a href="https://stocktwits.com/symbol/CRVO"><img style="aspect-ratio:1318/318;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/CRVO_sentiment_and_message_volume_Nov_27_premarket_7ed58203f3.png" alt="CRVO sentiment and message volume Nov 27 premarket.png" width="1318" height="318"></a><figcaption>CRVO sentiment and message volume Nov 27 premarket as of 9:15 am ET | source: Stocktwits</figcaption></figure>On Stocktwits, the sentiment surrounding CervoMed shifted dramatically from ‘bearish’ to ‘extremely bullish,’ with a surge in message volume reflecting renewed optimism among retail investors.&nbsp;<stembedurl>https://stocktwits.com/ajmore/message/594262803</stembedurl><stembedurl>https://stocktwits.com/AnalRetort/message/594262019</stembedurl>While CervoMed’s stock has dipped 0.25% year-to-date, the latest news has reignited investor interest, propelling the stock to among the top 15 trending symbols before the bell on Wednesday.For updates and corrections email newsroom[at]stocktwits[dot]com.Read next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/amgn-stock-slips-premarket-after-rbc-cuts-price-target/cJI0wiDRW7">Amgen Stock Slips After More Analyst Criticism On Weight-Loss Drug Data: Retail Eyes ‘Great Buying Opportunity’</a>

Neflamapimod, currently undergoing a Phase 2b study in patients with early-stage dementia with Lewy bodies (DLB)

CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled

The Orphan Drug status provides CervoMed with several key benefits, including tax credits for clinical trial costs, regulatory assistance, and seven years of post-approval market exclusivity.

Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now

MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024. The...

Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now

MIAMI, April 02, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 69th Emerging Growth Conference on April 3 & 4, 2024...

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point

CervoMed: H2 2024 Data For DLB Program A Major Inflection Point...

CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. CervoMed, Inc. was founded in1995 and is headquartered in Boston, MA.

CervoMed Inc

Cut 25 bps

Cut 50+ bps

No change

Hike 25 bps

It’s Fed Decision Week. Polymarket gives a 90% chance of a 25 bps cut. What’s your call? 
 
*Powered by Polymarket

CRVO
CervoMed Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest CRVO News

CRVO CervoMed Inc